UK's cost agency rebuffs Bristol arthritis drug | Reuters
Links shared publicly online about this topic.
- 401total visits
UK's cost agency rebuffs Bristol arthritis drug | Reuters
LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended against using Bristol-Myers Squibb's rheumatoid arthritis drug Orencia on the state health service as a second-line treatment.The
View full resource at reuters.com
Tags: Arthritis, Arthritis Medication, Rheumatoid Arthritis, Rheumatoid Arthritis Medication, Drug, Healthcare, Bristol-Myers Squibb
Most Recently Shared on March 30, 2011 at 9:26 pm By:
UK's cost agency rebuffs Bristol arthritis drug http://reut.rs/hEmclt
Advertisement
